TY  - JOUR
PY  - 2021//
TI  - Are we repeating mistakes of the past? A review of the evidence for esketamine
JO  - British journal of psychiatry
A1  - Horowitz, Mark A.
A1  - Moncrieff, Joanna
SP  - 614
EP  - 617
VL  - 219
IS  - 5
N2  - Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Safety signals - deaths, including suicides, and bladder damage - were minimised.<p /> <p>Language: en</p>
LA  - en
SN  - 0007-1250
UR  - http://dx.doi.org/10.1192/bjp.2020.89
ID  - ref1
ER  -